Q2 Earnings Estimate for Journey Medical Issued By B. Riley

Key Points

• B. Riley has projected Journey Medical Corporation will report Q2 2025 earnings of ($0.06) per share, with full-year estimates for 2025 at ($0.25) EPS.
• In its last earnings release, Journey Medical reported a loss of $0.18 per share, exceeding the consensus estimate of ($0.24).
• The company has experienced shifts in analyst ratings, with Alliance Global Partners maintaining a "buy" rating, while Wall Street Zen downgraded it to a "hold".

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities researchers at B. Riley issued their Q2 2025 EPS estimates for shares of Journey Medical in a research note issued on Wednesday, July 30th. B. Riley analyst M. Mamtani forecasts that the company will earn ($0.06) per share for the quarter. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical's Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at $0.45 EPS, FY2027 earnings at $1.33 EPS, FY2028 earnings at $2.17 EPS and FY2029 earnings at $0.85 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.14 million during the quarter, compared to analyst estimates of $12.05 million. Journey Medical had a negative net margin of 14.76% and a negative return on equity of 52.03%.

Several other equities analysts have also weighed in on the stock. Wall Street Zen lowered shares of Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th.

Journey Medical Price Performance

Shares of NASDAQ:DERM traded up $0.14 during trading hours on Friday, hitting $7.13. 76,857 shares of the company's stock traded hands, compared to its average volume of 98,514. Journey Medical has a 52 week low of $3.54 and a 52 week high of $8.25. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.03 and a current ratio of 1.34. The company's fifty day simple moving average is $7.19 and its two-hundred day simple moving average is $6.29. The company has a market cap of $166.03 million, a price-to-earnings ratio of -18.27 and a beta of 0.80.

Institutional Investors Weigh In On Journey Medical

A number of large investors have recently made changes to their positions in the company. Titleist Asset Management LLC raised its holdings in shares of Journey Medical by 18.3% during the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after acquiring an additional 2,000 shares during the period. Cetera Investment Advisers raised its holdings in shares of Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after acquiring an additional 2,478 shares during the period. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Journey Medical by 3.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock valued at $1,994,000 after acquiring an additional 9,938 shares during the period. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Journey Medical during the second quarter valued at approximately $72,000. Finally, Kovitz Investment Group Partners LLC raised its holdings in shares of Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after acquiring an additional 13,105 shares during the period. Institutional investors and hedge funds own 7.25% of the company's stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.